Log in
Enquire now
‌

US Patent 9399775 RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases

Patent 9399775 was granted and assigned to Alnylam Pharmaceuticals on July, 2016 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Patent abstract

The present invention provides RNAi agents, e.g., double stranded RNAi agents, that target the transthyretin (TTR) gene and methods of using such RNAi agents for treating or preventing TTR-associated diseases.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9399775 RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.